19.10.2016 • NewsElaine BurridgeHaldor TopsoeCB&I

CB&I and Haldor Topsoe Partner on Syngas

US engineering contractor CB&I has signed an agreement for a long-term alliance on syngas with Danish catalysis and process technology company Haldor Topsoe. Under the deal, CB&I will promote Haldor Topsoe’s syngas-based technologies, which the US-firm said complements its existing portfolio. The alliance adds eight Haldor Topsoe process technologies to CB&I’s current offering of more than 90 technologies and 3,500 patents, while also allowing the US firm to capitalize on the Lyngby-headquartered company’s expertise in engineering, procurement and construction (EPC).

CB&I will also work with Haldor Topsoe on providing EPC services to plants in North America. Patrick Mullen, CB&I’s chief operating officer, said the alliance gives it additional competitive offerings to the industry, adding that the two companies have a long history of technology collaboration. Both companies are working together on a refinery upgrade for Pertamina in Indonesia. The project at Pertamina’s Unit V refinery in Balikpapan, East Kalimantan, will use CB&I’s CDAlky advanced sulfuric acid alkylation process and Haldor Topsoe’s wet gas sulfuric acid technology.

CDAlky is an environmentally friendly alternative route to obtain high-octane premium gasoline that eliminates the need for human contact with sulfuric acid.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read